Overview of preclinical and phase II clinical studies on Pegmolesatide’s long-term erythropoiesis stimulating effect via EPOR-mediated signal transduction

Overview of preclinical and phase II clinical studies on Pegmolesatide’s long-term erythropoiesis stimulating effect via EPOR-mediated signal transduction

Abstract Introduction Anemia is a prevalent complication of chronic kidney disease (CKD), primarily due to insufficient erythropoietin (EPO). Pegmolesatide (by Hansoh Pharma) is currently the only marketed long-acting EPO mimetic peptide (EMP) for the treatment of anemia in both dialysis and non-dia...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaoying Ma, Zhen Li, Lu Zhang, Hui Qian, Qinkai Chen, Ye Tao, Yunfan Li, Dandan Wang, Zhizhen Hu, Weili Luo, Ping Li, Hai Yu, Changlin Mei, Xueqing Yu, Yuanfeng Zhou
Format: Article
Language:English
Published: BMC 2025-02-01
Series:Journal of Translational Medicine
Subjects:
Anemia
Cell signaling
Cell survival
Chronic kidney disease
Online Access:https://doi.org/10.1186/s12967-025-06078-1
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12967-025-06078-1

Similar Items